Drug Discovery Committee

The Drug Discovery Committee (DDC) reviews applications for biotherapeutic and small molecule drug discovery research, and manages our strategic goals in the area of drug discovery.

The DDC funds and oversees Programme and Project Awards for biotherapeutics and small molecule cancer drug discovery, from target identification through to early preclinical studies. The DDC also oversees our Drug Discovery Units (DDUs) and translational research alliances.

The DDC meets twice a year, funding Project Awards in May and November, and Programme Awards at the May meeting.

Funding Schemes

Biotherapeutic Drug Discovery Programme Awards provide 5 years of support, and will be awarded to outstanding individuals with an established scientific track record to support the discovery and development of novel biological therapeutic agents.

Biotherapeutic Drug Discovery Project Awards provide short-term funding support for applications on therapeutic discovery and development approaches that are derived from biological sources such as antibody and cell based therapeutics.

Small Molecule Drug Discovery Project Awards support the identification and validation of novel therapeutic targets and the discovery and development of novel small molecule therapeutic agents, and are typically held for 2 years.

How proposals are judged

The DDC funds Project and Programme Awards that support milestone driven research, with the aim of developing new preventative or therapeutic entities. Applications are judged on the basis of their scientific excellence and strategic importance.

Our drug discovery infrastructure

To support our investigator-led drug discovery research we have made extensive investment in infrastructure for biotherapeutic and small molecule drug discovery.

Committee and panel members

Chair of the Drug Discovery Committee (acting)

Professor Justin Bryans – Medical Research Council Technology

Members of the Drug Discovery Committee

Dr Justin Bower/Dr Heather McKinnon – CRUK Beatson Institute (alternate meetings)

Professor Raj Chopra – The Institute of Cancer Research

Professor Adrian Harris – University of Oxford

Dr Donald Ogilvie – Independent

Dr Hamish Ryder – CRUK Therapeutic Discovery Laboratories

Dr Dennis Smith – Independent

Dr Caroline Springer – CRUK Manchester Institute

Dr John Tite – Independent

Professor Bart Vanhaesebroeck – University College London

Professor Steve Wedge – Northern Institute for Cancer Research

Chair of the Biotherapeutics Expert Review Panel

Dr John Tite – Independent

Members of the Biotherapeutics Expert Review Panel

Professor John Bell – Ottawa Health Research Insitute

Dr Stephen Martin – GlaxoSmithKline

Professor Alan Melcher – University of Leeds

Professor Rienk Offringa – DKFZ Heidelberg, Germany

Professor Karl Peggs – University College London

Professor Ben Willcox – University of Birmingham

Dr Gerald Willimsky – Charité Universitätsmedizin Berlin

Chair of the Small Molecule Expert Review Panel

Dr ​Dennis Smith – Independent

Vice-chair of the Small Molecule Expert Review Panel

Professor Steve Wedge – Northern Institute for Cancer Research

Members of the Small Molecule Expert Review Panel

Dr Udai Banerji – The Institute of Cancer Research

Dr Justin Bower – CRUK Beatson Institute

Professor Neil Carragher – The University of Edinburgh

Dr Christian Dillon – CRUK Therapeutic Discovery Labs

Dr Mathew Garnett – Sanger Institute

Dr Dan Niculescu-Duvaz – CRUK Manchester Institute

Dr Olivia Rossanese – The Institute of Cancer Research

Dr Anderson Ryan – University of Oxford

Contact for this committee

Dr Rupal Mistry

Research Funding Manager

drugdiscovery.committee@cancer.org.uk

Tel: +44 (0) 203 469 8732